Drug safety. Conflict-of-interest allegations derail inquiry into antidepressant's 'dark side'.
Bachtold
Daniel
D
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D016265:Conflict of Interest; D003866:Depressive Disorder / Q000188:drug therapy; D004345:Drug Industry; D005260:Female; D006801:Humans; D007449:Investments; D008297:Male; D017374:Paroxetine / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing / Q000592:standards*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D013405:Suicide; D006113:United Kingdom; D014754:Violence
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors